PLX-PAD
Cell therapy
Evidence outlook
Studies registered, no market-specific stage
Studies of this drug are registered, but none is matched to a market this site covers, so no stage is set and there is nothing to grade. The registry list shows each study.
Development in Atherosclerotic Cardiovascular Disease stopped for reasons the sponsor has not stated. Source
Development in Critical Limb Ischemia stopped (2020-12) after a negative readout. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
No matching registered study is currently available for this indication; source coverage requires resolution.
No registered study of this drug names Osteoarthritis in its conditions or title.
0 registry matches · 0 candidates
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Osteoarthritis: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| PLX-PAD: this drug | Stage not on record | Cell therapy | Mesenchymal stem cells (immunomodulatory, pro-angiogenic) | not yet graded | No reviewed efficacy summary in this indication | |
| Ecnoglutide | Phase 3 | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Eloralintide | Phase 3 | Peptide | Amylin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Orforglipron (Foundayo) | Phase 3 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Allocetra | Phase 2 | Cell therapy | Macrophage reprogramming | not yet graded | No reviewed efficacy summary in this indication | |
| Vutiglabridin | Phase 2 | Small molecule | paraoxonase-2 (PON2) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.